Screener
BioMarin Pharmaceuticals BMRN Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Payments of debt issuance costs | (65,604) | — |
| Net cash provided by (used in) financing activities | 3,551,547 | (43,382) |
| Effect of exchange rate changes on cash | (1,630) | (4,479) |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | (437,674) | 270,974 |
| Cash and cash equivalents: | ||
| Beginning of period | $1,311,679 | $942,842 |
| End of period | $874,005 | $1,213,816 |
| SUPPLEMENTAL CASH FLOW DISCLOSURES: |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's net change in cash?
- BioMarin Pharmaceuticals (BMRN) reported net change in cash of -$2.2B in Q2 2026.
- How has BioMarin Pharmaceuticals's net change in cash changed year-over-year?
- BioMarin Pharmaceuticals's net change in cash decreased by 1432.3% year-over-year, from $165.01M to -$2.2B.
- What is the long-term trend for BioMarin Pharmaceuticals's net change in cash?
- Over 2 years (2021 to 2025), BioMarin Pharmaceuticals's net change in cash has grown at a 144.1% compound annual growth rate (CAGR), from -$61.88M to $368.84M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about BioMarin Pharmaceuticals's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude